• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION AND THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • ADDICTION & DOPAMINE
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING BRAIN
      • FASTING CANCER
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUTAMATE & BRAIN
      • GLYCATION
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERINSULINEMIA
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • MENAQUINONE 4
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME EXTRACT
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON-OPIOID ANALGESICS (PLANT BASED)
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RECEPTOR “Κ OPIOID”
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    JAK INHIBITION ALLEVIATES SASP
    January 7, 2020
    JNK PREVENTS PREMATURE SENESCENCE
    January 10, 2020
    1. … : VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR–PI3K–AKT pathway (oncogene,(2018), 37, 41,(5585 …
    2. … and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation
    3. … and hormonal aspects of 6 human neoplasias with special emphasis on the presentation of the topological features of oncogene activation tumor suppressor gene …
    4. … associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation
    5. … b-lineage proto-oncogene b–deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance
    6. … chemically induced ha‐ras mutation and transformation of BALB/c 3T3 cells: Evidence for chemical‐specific activation and cell type—specific recruitment of oncogene …
    7. … coffee intake and serum concentrations of some organochlorine compounds are independently associated with the mutational activation of the K-ras oncogene.
    8. … energy particle radiation-associated oncogenic transformation in normal mice: insight into the connection between activation of oncotargets and oncogene …
    9. … Epstein–Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases
    10. … of chlordane in B6C3F1 and B6D2F1 male mice: evidence for regression in B6C3F1 mice and carcinogenesis independent of ras proto-oncogene activation
    11. … of CXC chemokines, growth-related oncogene α expression, and epithelial cell-derived neutrophil-activating protein-78 by ML-1 (interleukin-17F) involves activation …
    12. … of the chemokines monocyte chemotactic protein-1, regulated on activation normal T cell expressed and secreted protein, growth-related oncogene, and interferon-γ …
    13. … Overexpression of the Wild-Type Gsα as the gsp oncogene Initiates Chronic Extracellularly Regulated Kinase 1/2 Activation and Hormone Hypersecretion in Pituitary …
    14. … pathway in response to human papillomavirus infection and over‐expressionof interleukin‐32 controls the expression of the humanpapillomavirus oncogene
    15. … pathway through F‐actin: F‐Actin, assembled in response to Galpha12/13 induced RhoA‐GTP, promotes dephosphorylation and activation of the YAP oncogene
    16. … T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene
    17. 1O Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
    18. 291. A Novel Safety Assay for Retroviral Vectors That Reproduces Lmo2 Proto-oncogene Insertional Activation Events
    19. A complex containing PBX2 contributes to activation of the proto-oncogene HOX11
    20. A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene
    21. A human cellular sequence implicated in trk oncogene activation is DNA damage inducible.
    22. A new mechanism of oncogenic activation: E26 retroviral v-ets oncogene has inverted the C-terminal end of the transcription factor c-ets-1
    23. A repetitive element containing a critical tyrosine residue is required for transcriptional activation by the EWS/ATF1 oncogene
    24. A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage
    25. A role for Z-DNA in transcriptional activation of the human c-myc oncogene by the vaccinia virus E3L protein
    26. A short-lived nuclear phosphoprotein encoded by the human ets-2 proto-oncogene is stabilized by activation of protein kinase C.
    27. A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase.
    28. A study on the activation of oncogene and inactivation of suppressor gene in human gastric cancer
    29. A study on the activation of oncogene and inactivation of suppressor gene in human gastric cancer
    30. Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic
    31. Aberrant splicing events that are induced by proviral integration: implications for myb oncogene activation
    32. Abl oncogene bypasses normal regulation of Jak/STAT activation
    33. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs.
    34. Absence of Kirsten-ras oncogene activation in B-cell chronic lymphocytic leukemia
    35. Absence of ras oncogene activation in rat urinary bladder carcinomas induced by N-methyl-N-nitrosourea or N-butyl-N(4-hydroxybutyl)nitrosamine
    36. Abstract A08: Fast and efficient generation of conditional ROSA26-based mouse models that recapitulate oncogene activation in T-cell acute lymphoblastic leukemia
    37. Abstract A43: TFG-TEC oncogene modulates beta-enolase expression via both promoter activation and epigenetic modification
    38. Abstract B22: oncogene activation of K‐ras in resident myofibroblasts leads to development of spontaneous bronchioalveolar carcinoma in mice
    39. Abstract C131: HSP27 is necessary in cells showing oncogene hyper-activation.
    40. Abstract LB-128: The N-terminus of the ASPP2 tumor suppressor binds Ras and enhances Ras/Raf/MEK activation to promote oncogene-induced cellular senescence
    41. Abstract P1-06-05: Mre11 mediates a p53-independent quiescence program in response to mammary oncogene activation
    42. Abstract P6-03-04: Amplification of the WHSC1L1 oncogene regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is …
    43. Abstract# 4928: Impact of the targeted activation of the PLAG1 proto-oncogene in salivary glands, mammary glands, adipose tissue and pancreas of PLAG1 …
    44. Activation and expression of the K-ras oncogene in mouse lung tumorigenesis.
    45. Activation and Specificity of Aflatoxin B1 Binding on hhcM, a Human oncogene of Low Efficiency, and Cell Transformation
    46. Activation mechanism of the N-ras oncogene in human leukemias detected by synthetic oligonucleotide probes
    47. Activation of a cellular oncogene (c-mos) by DNA transposition
    48. ACTIVATION OF A CELLULAR oncogene (C-MOS) BY DNA TRANSPOSITION.
    49. Activation of a cellular oncogene by DNA rearrangement: possible involvement of an IS-like element
    50. Activation of a cellular proto-oncogene in spontaneous liver tumor tissue of the B6C3F1 mouse
    51. Activation of a cK-ras oncogene by somatic mutation in mouse lymphomas induced by gamma radiation
    52. Activation of a mcf. 2 oncogene by deletion of amino-terminal coding sequences.
    53. Activation of a muscle-specific enhancer by the Ski proto-oncogene
    54. Activation of a novel proto‐oncogene, Frat1, contributes to progression of mouse T‐cell lymphomas
    55. Activation of anthraquinone biosynthesis in long-cultured callus culture of Rubia cordifolia transformed with the rolA plant oncogene
    56. Activation of c-Ha-ras proto-oncogene by in vitro chemical modification with 2-amino-6-methyldipyrido [1, 2-a: 3′, 2′-d] imidazole (Glu-P-1) and 4-nitroquinoline N-oxide …
    57. Activation of c-Ha-ras-1 proto-oncogene by in vitro modification with a chemical carcinogen, benzo (a) pyrene diol-epoxide
    58. Activation of c-mos oncogene by integration of an endogenous long terminal repeat element during transfection of genomic DNA from mouse skin tumor cells.
    59. Activation of CCND1 oncogene in nasopharyngeal carcinoma
    60. Activation of cell cycle arrest and apoptosis by the proto-oncogene Pim-2
    61. Activation of cellular oncogenes in human and mouse leukemia-lymphomas: spontaneous and induced oncogene expression in murine B lymphocytic neoplasms
    62. Activation of endogenous c-fos proto-oncogene expression by human T-cell leukemia virus type I-encoded p40tax protein in the human T-cell line, Jurkat.
    63. Activation of Expression of the c‐fos oncogene by UVA Irradiation in Cultured Human Skin Fibroblasts
    64. Activation of fibroblast growth factor receptor 3 and oncogene‐induced senescence in skin tumours
    65. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene
    66. Activation of H- ras oncogene in 3-methylcholanthrene-transformed human cell line
    67. Activation of H-ras oncogene in Rat Bladder Tumors Induced by N-Butyl-N-(4-hydroxybutyl)nitrosamine1
    68. Activation of Harvey ras oncogene by mutation at codon 12 is very rare in hemopoietic malignancies.
    69. Activation of heat shock protein (hsp) 70 and proto-oncogene expression by alpha1 adrenergic agonist in rat aorta with age.
    70. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL
    71. Activation of human papillomavirus type 18 E6–E7 oncogene expression by transcription factor Sp1
    72. Activation of IL-2 receptor alpha-chain gene by individual members of the rel oncogene family in association with serum response factor.
    73. Activation of Mas oncogene-Related G Protein–Coupled Receptors Inhibits Neurochemical Alterations in the Spinal Dorsal Horn and Dorsal Root Ganglia Associated …
    74. Activation of Mas oncogene-related gene (Mrg) C receptors enhances morphine-induced analgesia through modulation of coupling of μ-opioid receptor to Gi-protein …
    75. Activation of mouse osteoblast growth hormone receptor: c-fos oncogene expression independent of phosphoinositide breakdown and cyclic AMP
    76. Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogene FNDC3B
    77. Activation of multiple oncogene pathways: a model for experimental carcinogenesis
    78. Activation of N-myc oncogene and associated genes to chemoresistance, prognostic value for neuroblastoma
    79. Activation of nuclear factor kappa B and oncogene expression by 12 (R)-hydroxyeicosatrienoic acid, an angiogenic factor in microvessel endothelial cells.
    80. Activation of oncogene c‐Ha‐ras in gastric cancer of chinese patients
    81. Activation of oncogene expression in psoriatic lesions
    82. Activation of oncogenicity of the c-rel proto-oncogene.
    83. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants.
    84. Activation of phosphatidylinositol-3 kinase by nerve growth factor involves indirect coupling of the trk proto-oncogene with src homology 2 domains
    85. Activation of protease‐activated receptors in astrocytes evokes a novel neuroprotective pathway through release of chemokines of the growth‐regulated oncogene …
    86. Activation of proto-oncogene c-fos in the auditory tract of rats stimulation with wide-band noise
    87. Activation of proto-oncogene expression by growth regulatory signals
    88. Activation of PyMT in β Cells Induces Irreversible Hyperplasia, but oncogene-Dependent Acinar Cell Carcinomas When Activated in Pancreatic Progenitors
    89. Activation of ras oncogene in aflatoxin-induced rat liver carcinogenesis
    90. Activation of ras oncogene in livers with cirrhosis
    91. Activation of ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia
    92. Activation of specific glutamate receptor subtypes increases c-fos proto-oncogene expression in primary cultures of neonatal rat cerebellar granule cells
    93. Activation of spinal MrgC-Gi-NR2B-nNOS signaling pathway by Mas oncogene-related gene C receptor agonist bovine adrenal medulla 8-22 attenuates bone …
    94. Activation of the abl oncogene and its involvement in chromosomal translocations in human leukemia
    95. Activation of the abl oncogene in murine and human leukemias
    96. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties.
    97. Activation of the c-fos Proto-oncogene in the Spinal Cord Following Noxious Stimulation of the Urinary Bladder
    98. Activation of the c-Ki-ras oncogene in aflatoxin B1-induced hepatocellular carcinoma and adenoma in the rat: detection by denaturing gradient gel electrophoresis.
    99. Activation of the c-mos oncogene in a mouse plasmacytoma by insertion of an endogenous intracisternal A-particle genome
    100. Activation of the c-myc oncogene
    101. Activation of the c-myc oncogene by the immunoglobulin heavy-chain gene enhancer after multiple switch region-mediated chromosome rearrangements in a murine …
    102. Activation of the c-myc oncogene in a Precursor-B-Cell Blast Crisis of Follicular Lymphoma, Presenting as Composite Lymphoma
    103. Activation of the c-myc oncogene in B and T lymphoid tumors
    104. Activation of the c-ski oncogene by overexpression.
    105. Activation of the c‐Ha‐ras‐1 proto‐oncogene by methylation in vitro with α‐acetoxy‐N‐nitrosodimethylamine
    106. Activation of the cellular oncogene c-erbB by LTR insertion: molecular basis for induction of erythroblastosis by avian leukosis virus
    107. Activation of the cellular proto-oncogene product p21Ras by addition of a myristylation signal
    108. Activation of the cH-ras proto-oncogene by retrovirus insertion and chromosomal rearrangement in a Moloney leukemia virus-induced T-cell leukemia.
    109. Activation of the cK-ras oncogene in a human pancreas carcinoma
    110. Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene
    111. Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype
    112. Activation of the GLI oncogene through fusion with the β-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t (7; 12)
    113. Activation of the H-ras oncogene in hepatocellular carcinomas initiated with diethylnitrosamine and promoted by a dietary methyl deficiency
    114. Activation of the Ha-ras oncogene in tumors induced in mice by transplacental exposure to 7, 12-dimethylbenz (a) anthracene
    115. Activation of the human c-Ha-ras-1 proto-oncogene by in-vitro reaction with N-nitrosomethyl (acetoxymethyl) amine.
    116. Activation of the JNK pathway is essential for transformation by the Met oncogene
    117. Activation of the K-ras oncogene in liver tumors of Hudson River tomcod
    118. Activation of the K‐ras oncogene in colorectal neoplasms is Associated with decreased apoptosis
    119. Activation of the Lbc Rho exchange factor proto-oncogene by truncation of an extended C terminus that regulates transformation and targeting
    120. Activation of the M-CSF gene in mouse macrophages immortalized by retroviruses carrying a v-myc oncogene.
    121. Activation of the mas oncogene during transfection of monoblastic cell line DNA.
    122. Activation of the mas oncogene involves coupling to human alphoid sequences.
    123. Activation of the met oncogene in the human MNNG-HOS cell line involves a chromosomal rearrangement
    124. Activation of the met Proto-oncogene in
    125. Activation of the met Proto-oncogene in a Human Cell Line
    126. Activation of the N-myc2 oncogene by woodchuck hepatitis virus integration in the linked downstreamb3nLocus in woodchuck hepatocellular carcinoma
    127. Activation of the Na+/H+-exchanger is NIH 3T3 fibroblasts expressing the Ha-ras oncogene requires stimulated calcium influx and is associated with rearrangement of …
    128. Activation of the oncogene ERG by the Ras/ERK and PI3K/AKT pathways
    129. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis
    130. Activation of the proto-oncogene c-myc and c-fos by c-ras: involvement of polyamines
    131. Activation of the proto-oncogene p60c-src by point mutations in the SH2 domain.
    132. Activation of the ras oncogene and its relationship to aflatoxins-DNA adduct formation in the rat liver treated with aflatoxins
    133. Activation of the receptor kinase domain of the trk oncogene by recombination with two different cellular sequences.
    134. Activation of the ret oncogene in human thyroid carcinomas
    135. Activation of the ret-II oncogene without a sequence encoding a transmembrane domain and transforming activity of two ret-II oncogene products differing in carboxy …
    136. Activation of the T-Cell oncogene LMO2 after Gene Therapy for X-Linked Severe Combined Immunodeficiency
    137. Activation of the transforming potential of the human fos proto-oncogene requires message stabilization and results in increased amounts of partially modified fos …
    138. Activation of the trk oncogene by alternatively spliced muscle and non-muscle tropomyosin sequences.
    139. Activation of the Xmrk proto-oncogene of Xiphophorus by overexpression and mutational alterations
    140. Activation of transcription of the melanoma inducing Xmrk oncogene by a GC box element
    141. Activation of v‐Myb avian myeloblastosis viral oncogene homolog‐like2 (MYBL2)‐LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of …
    142. Agent-specific ras oncogene activation in rat thyroid tumours.
    143. AIMP3 haploinsufficiency disrupts oncogene-induced p53 activation and genomic stability
    144. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer
    145. Alkylating agent-induced mutagenesis and activation of the Ha-ras oncogene
    146. Alpha 1 adrenergic receptor activation of proto-oncogene expression in arterial smooth muscle: regulation by nitric oxide and vascular injury.
    147. Amplification and activation of c-Ki-ras oncogene in cell line developed from human pancreas explants.
    148. Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation
    149. An analysis of oncogene activation in ovarian carcinoma
    150. An atypical t(12;15) translocation of chromosomes found in murine plasmacytomas and activation of the c‐myc oncogene
    151. An experimental model for oncogene activation during tumor progression in vivo.
    152. An hsRPB4/7-dependent yeast assay for trans-activation by the EWS oncogene
    153. Analysis of the activation of the myc family oncogene and of its stability over time in xenografted human lung carcinomas
    154. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.
    155. Angiogenesis Correlates with Vascular Endothelial Growth Factor Expression but not with Ki-ras oncogene Activation in Non-Small Cell Lung Carcinoma1
    156. Antisense repression of proto-oncogene c-Cbl enhances activation of the JAK-STAT pathway but not the ras pathway in epidermal growth factor receptor signaling
    157. Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain
    158. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early …
    159. Assessment of RET/PTC oncogene activation in thyroid nodules utilizing laser microdissection followed by nested RT-PCR
    160. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway
    161. Atypical mechanism of NF-κB activation by TRE17/ubiquitin-specific protease 6 (USP6) oncogene and its requirement in tumorigenesis
    162. B‐raf oncogene: Activation by Rearrangements and Assignment to Human Chromosome 7
    163. bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    164. Blaydes, JP et al. Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. oncogene 19, 3829-3839
    165. BRCA1 chromatin dissociation induced by oncogene activation promotes formation of senescence-associated heterochromatin foci and senescence via chromatin …
    166. c-fos protein can induce cellular transformation: A novel mechanism of activation of a cellular oncogene
    167. c‐fos proto‐oncogene expression in human NK/LGL cells: Expression is not constitutive and is associated with functional activation
    168. C3G-mediated suppression of oncogene-induced focus formation in fibroblasts involves inhibition of ERK activation, cyclin A expression and alterations of …
    169. CAMAL: a new prognostic marker for remission in acute nonlymphoblastic leukemia Absence of kirsten-ras oncogene activation in B-cell chronic lymphocytic leukemia …
    170. Can oncogene (RAS) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to …
    171. Cancer upregulated gene 2, a novel oncogene, enhances migration and drug resistance of colon cancer cells via STAT1 activation
    172. Carcinogenic metalloid arsenic induces expression of mdig oncogene through JNK and STAT3 activation
    173. Carcinogenicity, metabolism and Ki-ras proto-oncogene activation by 7, 12-dimethylbenz[a] anthracene in rainbow trout embryos
    174. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene
    175. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene
    176. Cell type-specific E2F activation and cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I
    177. Cell type‐specific conditional regulation of the c‐myc proto‐oncogene by combining Cre/loxP recombination and tamoxifen‐mediated activation
    178. Cellular analysis of the kinetics of alpha-fetoprotein and nuclear oncogene activation in primary cultures of adult rat hepatocytes stimulated by epidermal growth factor
    179. Cellular oncogene activation
    180. Cellular oncogene Activation by Chromosomal Translocation
    181. Cellular oncogene activation by human cytomegalovirus lack of correlation with virus infectivity and immediate early gene expression
    182. Cellular oncogene activation: edited by George Klein, Marcel Dekker, 1988. $110.00 (USA and Canada), $132.00 (elsewhere)(xv+ 396 pages) ISBN 0 8247 7983 5
    183. Centrosome aberrations and spindle defects in thyroid carcinoma cells harboring specific oncogene activation
    184. Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene.
    185. CHIP functions as an oncogene by promoting colorectal cancer metastasis via activation of MAPK and AKT signaling and suppression of E-cadherin
    186. Chromatin Alterations in a Model of oncogene Activation Studied by Advanced Fluorescence Microscopy
    187. Chromosome abberation and oncogene activation in two histologically related human and rat B-cell tumors
    188. Chromosome Break-Points, Somatic Mutation and oncogene Activation: Some Comments
    189. Chromosome rearrangements and oncogene activation in thyroid tumors
    190. Chromosome translocations and the activation of C-myc oncogene in mouse plasmacytomas
    191. Clinical implications of oncogene activation in human neuroblastomas
    192. Clinical significance of K-ras oncogene activation in ampullary neoplasms.
    193. Clinical significance of ras oncogene activation in human lung cancer
    194. ClinicI significance of ras oncogene activation in human hmg cancer
    195. Cloning and activation of the Syrian hamster neu proto-oncogene
    196. Cloning of the murine c-fgr proto-oncogene cDNA and induction of c-fgr expression by proliferation and activation factors in normal bone marrow-derived monocytic …
    197. Colony stimulating factor‐1 (CSF‐1) stimulates temperature dependent phosphorylation and activation of the RAF‐1 proto‐oncogene product.
    198. Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency
    199. Comparison of K‐ras oncogene Activation in Pancreatic Duct Carcinomas and Cholangiocarcinomas Induced in Hamsters by N‐Nitrosobis(2‐hydroxypropyl)amine
    200. Complement activation causes oncogene expression in Gaucher disease
    201. Concomitant activation of the PI3K-Akt and the Ras-ERK signaling pathways is essential for transformation by the V-SEA tyrosine kinase oncogene
    202. Conditional deletion of Pten tumor suppressor gene and activation of K-Ras oncogene result in the development of Neurofibromatoses
    203. Constitutive activation of a variant of the env-mpl oncogene product by disulfide-linked homodimerization.
    204. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells
    205. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
    206. Constitutive macropinocytosis in oncogene-transformed fibroblasts depends on sequential permanent activation of phosphoinositide 3-kinase and phospholipase C
    207. Contribution of the activation of the ras oncogene to the evolution of aldosterone-and renin-secreting tumors.
    208. Correlation of Thyroid Hormone Dose-dependent Regulation of K-ras Protoncogene Expression with oncogene Activation by 3-Methylcholanthrene: Loss of Thyroidal …
    209. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53 …
    210. Correspondence re: G. Tallini et al., RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly …
    211. COT Kinase Proto-oncogene Expression in T Cells IMPLICATION OF THE JNK/SAPK SIGNAL TRANSDUCTION PATHWAY INCOT PROMOTER ACTIVATION
    212. CRISPR/Cas9-Based Approaches for Investigating Mechanisms of oncogene Activation and Tumor Suppression
    213. DDB1-CUL4 and MLL1 mediate oncogene-induced p16INK4a activation
    214. Deletion variants within the NF-kappaB activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in …
    215. Deletion Variants within the NF-kB Activation Domain of the LMP1 oncogene in Acquired Immunodeficiency Syndrome-Related Large Cell Lymphomas, in …
    216. Deletion Variants Within the NF-KB Activation Domain of the LMPl oncogene Prevail in Acquired Immunodeficiency Syndrome-Related Large Cell Lymphomas …
    217. DELETIONS AND MUTATIONS WITHIN THE NF-κB ACTIVATION DOMAIN OF THE LATENT MEMBRANE PROTEIN 1 (LMP1) oncogene OCCUR DURING LONG …
    218. DELETIONS AND MUTATIONS WITHIN THE NF-κB ACTIVATION DOMAIN OF THE LATENT MEMBRANE PROTEIN 1 (LMP1) oncogene OCCUR DURING LONG …
    219. Demonstration of cytogenesis of pancreas ductal carcinomas by conditional activation of mutated human Ha-ras oncogene in vivo in the rat
    220. Desmoglein 3 acts as a potential oncogene in promoting cancer cell migration and invasion through regulating AP-1 and PKC dependent-Ezrin activation
    221. Detection of K-ras oncogene activation in human lung cancer and its possible clinical application
    222. Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation
    223. Development of multidrug resistance due to multiple factors including P‐glycoprotein overexpression under K‐selection after MYC and HRAS oncogene activation
    224. Diagnosis of papillary thyroid carcinoma is facilitated by using an RT-PCR approach on laser-microdissected archival material to detect RET oncogene activation
    225. Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells
    226. Different mechanisms are responsible for oncogene activation in human mammary neoplasia
    227. Differential activation of the c-Ki-ras-2 proto-oncogene in human colorectal carcinoma.
    228. Differential Activity of the KRAS oncogene by Method of Activation: Implications for Signaling and Therapeutic Intervention
    229. Direct trans-activation of the human cyclin D2 gene by the oncogene product Tax of human T-cell leukemia virus type I
    230. DNA amplification is a common mechanism of oncogene activation in lung cancer
    231. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers
    232. DNA Damage Response and Genetic Instability; AIMP3 Haploinsufficiency inhibit p53 activation by oncogene including Ras and c-myc, result to Genomic instability
    233. Dominant-negative Rac1 suppresses Ras-induced apoptosis possibly through activation of NFκB in Ha-ras oncogene-transformed NIH/3T3 cells
    234. Dose dependency of aflatoxin B1 binding on human high molecular weight DNA in the activation of proto-oncogene.
    235. Dose-dependent activation of putative oncogene SBSN by BORIS
    236. Dose-dependent carcinogenicity and frequent Ki-ras proto-oncogene activation by dietary N-nitrosodiethylamine in rainbow trout
    237. Double PIK3CA mutations in cis enhance oncogene activation and sensitivity to PI3K alpha inhibitors in breast cancer
    238. Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene
    239. Drosophila actin-Capping Protein limits JNK activation by the Src proto-oncogene
    240. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
    241. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha- ras oncogene in rat pancreas
    242. E2F1 induction following DNA damage and oncogene activation
    243. Early activation of the proto-oncogene c-fgr during Epstein-Barr virus immortalization
    244. Early biochemical markers of effects: enzyme induction, oncogene activation and markers of oxidative damage
    245. Early biochemical markers of effects: enzyme induction, oncogene activation and markers of oxidative damage
    246. Early effects of transplatin on oncogene activation in vivo
    247. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma
    248. Effect of activation of HOX11 proto-oncogene on prognosis of acute leukemia in children [J]
    249. Effect of oncogene expression on telomerase activation and telomere length in human endothelial, fibroblast and prostate epithelial cells.
    250. Effects of v-src oncogene Activation on Radiation Sensitivity in Drug-Sensitive and in Multidrug-Resistant Rat Fibroblasts
    251. EGF promotes development of a differentiated trophoblast phenotype having c-myc and junB proto-oncogene activation
    252. ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation
    253. Epigenetic activation of WHSC1 functions as an oncogene and is associated with poor prognosis in cervical cancer
    254. Establishment of Murine Lung Alveolar Epithelial Cell Lines from Lung Tumors Initiated by Somatic Activation of the K-ras oncogene.
    255. Ets and retroviruses–transduction and activation of members of the Ets oncogene family in viral oncogenesis
    256. ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex
    257. Evaluating the safety of retroviral vectors based on insertional oncogene activation and blocked differentiation in cultured thymocytes
    258. Evidence for long‐range oncogene activation by hepadnavirus insertion.
    259. Evidence that the ras oncogene-encoded p21 protein induces oocyte maturation via activation of protein kinase C.
    260. Expression of FLJ10540, a novel oncogene, is associated with liver carcinogenesis and tumor progression through the activation of PKB/AKT pathway
    261. Expression of major histocompatibility class I genes in differentiating leukemic cells is temporally related to activation of c-fos proto-oncogene.
    262. Expression of the Bcl-3 proto-oncogene suppresses p53 activation
    263. Expression, Function and Activation of the Proto-oncogene c-kit Product in Human Leukemia Cells
    264. Extremely stringent activation of p16INK4a prevents immortalization of uterine cervical epithelial cells without human papillomavirus oncogene expression
    265. Fastest Time to Cancer by Loss of Tumor Suppressor Genes or oncogene Activation
    266. Felis catus papillomavirus type 2 E6 oncogene enhances mitogen-activated protein kinases and Akt activation but not EGFR expression in an in vitro feline model of …
    267. Folic acid mediates activation of the pro-oncogene STAT3 via the Folate Receptor alpha
    268. Follicle-stimulating hormone induces multiple signaling cascades: evidence that activation of Rous sarcoma oncogene, RAS, and the epidermal growth factor receptor …
    269. Frequent activation of the Ki‐ras oncogene at codon 12 in N‐methyl‐N‐nitrosourea‐induced rat prostate adenocarcinomas and neurogenic sarcomas
    270. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation
    271. Frequent multiple c‐ki‐ras oncogene activation in pancreatic juice from patients with benign pancreatic cysts
    272. Function-dependent cooperation between oncogene activation and nonrandom chromosome change during tumorigenic conversion of Syrian hamster cells
    273. Generation of a double binary transgenic zebrafish model to study myeloid gene regulation in response to oncogene activation in melanocytes
    274. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas
    275. Genome-wide examination of topological variability reveals cell type-specific mechanisms of oncogene activation
    276. Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer
    277. Genomic effects of the putative oncogene G alpha s. Chronic transcriptional activation of the c-fos proto-oncogene in endocrine cells.
    278. GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer
    279. Growth factor biology and oncogene activation in human gliomas and their implications for specific therapeutic concepts
    280. Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene
    281. GTPγS activation of proto‐oncogene expression in transiently permeabilised Swiss 3T3 fibroblasts
    282. H-ras oncogene Activation in Invasive UVR-Induced Corneal Sarcomas of the Opossum Monodelphis domestica
    283. Ha-ras oncogene activation in mammary glands of N-methyl-N-nitrosourea-treated rats genetically resistant to mammary adenocarcinogenesis.
    284. Ha-ras oncogene induction of invasion and metastasis is associated with the activation and redistribution of protease (s) in rat-kidney cells
    285. Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell.
    286. Hepatitis B virus integration and oncogene activation
    287. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells
    288. High frequency of mas oncogene activation detected in the NIH3T3 tumorigenicity assay.
    289. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.
    290. High Frequency of ras oncogene Activation in Benign and Malignant Human Thyroid Tumours
    291. HIGH FREQUENCY OF!~~ oncogene ACTIVATION
    292. High Iodine Concentration Attenuates RET/PTC3 oncogene Activation in Thyroid Follicular Cells
    293. High prevalence of RET proto-oncogene activation (RET/PTC) in papillary thyroid carcinomas
    294. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene
    295. Higher frequency of ras oncogene activation in gastric stump carcinomas due to special conditions in the gastric remnant
    296. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry
    297. Homeobox oncogene activation by pan-cancer DNA hypermethylation
    298. Human c-fos proto-oncogene mapped to chromosome 14, band q24. 3–q31 possibilities for oncogene activation by chromosomal rearrangements in human …
    299. Hyperpolarized 13C Magnetic Resonance Spectroscopy: Probing Enzymatic Activity, Cellular Transport, and oncogene Activation
    300. Hyperpolarized 13C Magnetic Resonance Spectroscopy: Probing Enzymatic Activity, Cellular Transport, and oncogene Activation
    301. Hypomethylation mediated by decreased DNMTs involves in the activation of proto-oncogene MPL in TK6 cells treated with hydroquinone
    302. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit …
    303. In vitro activation of the human Harvey-ras proto-oncogene by aflatoxin B1.
    304. In vitro activity of the EWS oncogene transcriptional activation domain
    305. In vitro transformation of rat cells by 3-methylcholanthrene: activation of the ras oncogene
    306. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung
    307. Incidence of ras oncogene activation in lung carcinomas in Hong Kong
    308. Influence of HPV16 E7 oncogene activation on the expression of cdc25A and cyclin E in HeLa cells [J]
    309. Influence of oleic acid on the expression, activation and activity of gelatinase a produced by oncogene‐transformed human bronchial epithelial cells
    310. Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and upregulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced …
    311. Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non–small cell lung cancer
    312. Initiation factor eIF2B not p70 S6 kinase is involved in the activation of the PI‐3K signalling pathway induced by the v‐src oncogene
    313. Insulator dysfunction and epigenetic oncogene activation in SDH-deficient gastrointestinal stromal tumor
    314. Insulator dysfunction and oncogene activation in IDH mutant gliomas
    315. Insulator dysfunction and oncogene activation in IDH mutant gliomas
    316. Integration of transfected LTR sequences into the c‐raf proto‐oncogene: activation by promoter insertion.
    317. Interaction between the adhesion receptor, CD44, and the oncogene product, p185 HER2, promotes human ovarian tumor cell activation
    318. Interleukin-1 activation of FOS proto-oncogene protein in the rat hypothalamus
    319. Intragenic recruitment of NF-κB drives alternative splicing modifications upon activation by the viral oncogene TAX of HTLV-1
    320. Involvement of K-ras oncogene Activation in Formaldehyde-induced Rat Nasal Carcinoma
    321. Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours
    322. Isocitrate Dehydrogenase Mutation Leads to Alteration in 3-Dimensional DNA Structure and oncogene Activation in Gliomas
    323. Isoform-specific ras activation and oncogene dependence during MYC-and Wnt-induced mammary tumorigenesis
    324. K-ras oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung
    325. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction …
    326. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung
    327. K-ras oncogene Activation in Neoplasias of Patients with Familial Adenomatous Polyposis or Kidney Transplant
    328. K‐ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ras mutations are an early and irreversible event in the development of …
    329. Ki-ras oncogene activation in preinvasive pancreatic cancer
    330. Ki-ras oncogene activation in transplantable rat thyroid carcinoma induced by N-bis (2-hydroxypropyl) nitrosamine
    331. Kinetic evidence of a rapid activation of phosphatidylcholine hydrolysis by Ki-ras oncogene. Possible involvement in late steps of the mitogenic cascade.
    332. LINC01857 as an oncogene regulates CREB1 activation by interacting with CREBBP in breast cancer
    333. Lineage-Specific Epigenomic and Genomic Activation of the oncogene HNF4A Promotes Gastrointestinal Adenocarcinomas
    334. Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation
    335. Long-range effects of direct-hit ultraviolet and particle radiation in oncogene activation.
    336. Loss of Retinoic Acid Receptors in Mouse Skin and Skin Tumors Is Associated with Activation of the ras―@ oncogene and High Risk for Premalignant …
    337. Loss of retinoic acid receptors in mouse skin and skin tumors is associated with activation of the rasHa oncogene and high risk for premalignant progression
    338. Low frequency of detectable oncogene activation in rat liver and mammary tumors induced by a single dose of diethylnitrosamine and continuous treatment with 17 …
    339. Low incidence of ras oncogene activation in human squamous cell carcinomas
    340. Low rate of ret proto‐oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from saudi arabia
    341. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient
    342. Mastoparan transiently permeabilises Swiss 3T3 cells and induces c-fos proto-oncogene expression: Role of calcium and G protein activation
    343. Mature acinar cells are refractory to carcinoma development by targeted activation of Ras oncogene in adult rats
    344. Mechanism of activation and biological role of the c-myc oncogene in B-cell lymphomagenesis
    345. Mechanism of activation of a human oncogene
    346. Mechanism of activation of a human oncogene
    347. Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells
    348. Mechanism of activation of the human trk oncogene.
    349. Mechanism of activation of the mouse c‐mos oncogene by the LTR of an intracisternal A‐particle gene.
    350. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.
    351. Mechanism of activation of thec-myc oncogene in Burkitt lymphoma: Structural and functional characterization of the 5’region ofc-myc.
    352. Mechanism of estrogen activation of c-myc oncogene expression.
    353. Mechanism of H-ras oncogene activation in mouse squamous carcinoma induced by an alkylating agent
    354. Mechanism of met oncogene activation
    355. Mechanism of oncogene Activation or Antioncogene Inactivation by External Factors
    356. Mechanism of oncogenesis and activation of oncogene in human ovarian carcinoma
    357. Mechanism of transcriptional activation by the proto-oncogene Twist1
    358. Mechanisms of oncogene cooperation: activation and inactivation of a growth antagonist.
    359. Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes
    360. MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-κB activation
    361. met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre‐clinical model of human osteosarcoma
    362. Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters
    363. Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and rat 1a cells.
    364. MMTV-cre-mediated fur inactivation concomitant with PLAG1 proto-oncogene activation delays salivary gland tumorigenesis in mice
    365. MNU-induced point mutation and activation of c-Ha-ras oncogene in cell lines derived from human pancreas explants.
    366. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15
    367. Modes of c-myc oncogene activation in murine plasmacytomas
    368. Molecular and biochemical bases for activation of the transforming potential of the proto-oncogene c-ros.
    369. Molecular Genetic Alterations such as oncogene Activation as a Tool for the Evaluation of Risks in Chemical Carcinogenesis
    370. Molecular Genetics of oncogene Activation and Gene Loss in Carcinogen-Induced Animal Tumours
    371. Molecular mechanism of estrogen activation of c-myc oncogene expression in human breast cancer cells
    372. Molecular mechanism of the activation of the ret/ptc1 oncogene in papillary thyroid carcinomas and characterization of the promoter of the rat sodium iodide …
    373. Molecular mechanisms of cadmium carcinogenesis: The potential roles of lipid peroxidation, oncogene activation and metallothionein expression
    374. Molecular mechanisms of oncogene-induced inflammation and inflammation-sustained oncogene activation in gastrointestinal tumors: An underappreciated symbiotic …
    375. Mouse c-mos oncogene activation is prevented by upstream sequences
    376. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene
    377. Multiple mechanisms of oncogene activation in viral and nonviral neoplasia
    378. Multiple oncogene activation in a radiation carcinogenesis model
    379. Multistep Scenarios in Tumor Development and the Role of oncogene Activation by Chromosomal Translocations
    380. Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding.
    381. Mutational activation of c-Ha-ras oncogene or cancer promotion by phenobarbital upregulates the transcription of c-jun and c-myc oncogene in N-nitrosodiethylamine …
    382. Mutational activation of H-ras oncogene transformability by alkylnitrosourea-induced DNA damage
    383. Mutational activation of k-ras oncogene in human breast-tumors
    384. Mutational activation of the cellular Harvey ras oncogene in rat esophageal papillomas induced by methylbenzylnitrosamine
    385. Mutational Activation of the K-ras oncogene
    386. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
    387. Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms’ tumors
    388. Myc oncogene activation in B and T lymphoid tumours
    389. N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence
    390. N–methyl-d-aspartate receptors mediate activation of the c-fos proto-oncogene in a model of brain injury
    391. N-Nitrosocimetidine as an initiator of murine skin tumors with associated H-ras oncogene activation
    392. Nanoscale ChIP-seq analysis in primary hepatocellular carcinoma tissues reveals tumor-specific chromatin deregulation for oncogene activation
    393. New knowledge on the molecular mechanism of activation of oncogenes and effect of oncogene DNA on protein synthesis
    394. Nucleotide sequence of chicken c-myb complementary DNA and implications for myb oncogene activation
    395. Nucleotide sequence of testis-derived c-abl cDNAs: implications for testis-specific transcription and abl oncogene activation
    396. oncogene activation
    397. oncogene activation and apoptosis as possible mechanism of antitumour effect of ferric-sorbitol-citrate
    398. oncogene activation and breast cancer progression